Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Eur J Heart Fail
; 10(2): 157-63, 2008 Feb.
Article
in En
| MEDLINE
| ID: mdl-18242128
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Spironolactone
/
Tetrazoles
/
Benzimidazoles
/
Angiotensin-Converting Enzyme Inhibitors
/
Adrenergic beta-Antagonists
/
Mineralocorticoid Receptor Antagonists
/
Heart Failure
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Eur J Heart Fail
Journal subject:
CARDIOLOGIA
Year:
2008
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
United kingdom